Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer
出版年份 2019 全文链接
标题
Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer
作者
关键词
miR-218-3p, Exosome, Colorectal cancer, Chemoresistance, Epithelial-mesenchymal transition, Drug efflux
出版物
Molecular Cancer
Volume 18, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-03-19
DOI
10.1186/s12943-019-0981-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer
- (2018) Christian Breunig et al. Molecular Oncology
- Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer
- (2018) Tian Fang et al. Nature Communications
- miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis
- (2018) Bo Lian et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes
- (2018) Altanerova Ursula et al. INTERNATIONAL JOURNAL OF CANCER
- Exosomes and their importance in metastasis, diagnosis, and therapy of colorectal cancer
- (2018) Hamid Cheshomi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Effect of exosomal miRNA on cancer biology and clinical applications
- (2018) Zhenqiang Sun et al. Molecular Cancer
- MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
- (2017) Peilong Li et al. MOLECULAR CANCER THERAPEUTICS
- Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
- (2017) Sushrut Kamerkar et al. NATURE
- Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC
- (2017) Junchao Cai et al. Nature Communications
- Prognostic Value of microRNA Signature in Patients with Gastric Cancers
- (2017) Hai-Ting Liu et al. Scientific Reports
- Extracellular vesicles for drug delivery
- (2016) Pieter Vader et al. ADVANCED DRUG DELIVERY REVIEWS
- Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
- (2016) Le Qu et al. CANCER CELL
- Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis
- (2015) Yan Li et al. CELL RESEARCH
- Exosomes in cancer: small particle, big player
- (2015) Xu Zhang et al. Journal of Hematology & Oncology
- miR-124, -128, and -137 Orchestrate Neural Differentiation by Acting on Overlapping Gene Sets Containing a Highly Connected Transcription Factor Network
- (2015) Márcia C. T. Santos et al. STEM CELLS
- Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis
- (2014) Weiying Zhou et al. CANCER CELL
- Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
- (2014) X. Zhang et al. CLINICAL CANCER RESEARCH
- Extracellular vesicles as drug delivery systems: Lessons from the liposome field
- (2014) Roy van der Meel et al. JOURNAL OF CONTROLLED RELEASE
- Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
- (2014) Peter M. Wilson et al. Nature Reviews Clinical Oncology
- MicroRNAs -the Next Generation Therapeutic Targets in Human Diseases
- (2014) Sakthivel Srinivasan et al. Theranostics
- Friend or foe: the role of microRNA in chemotherapy resistance
- (2013) Haoran Li et al. ACTA PHARMACOLOGICA SINICA
- A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy
- (2013) Yanhua Tian et al. BIOMATERIALS
- Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth
- (2013) Mark Katakowski et al. CANCER LETTERS
- Self-renewal as a therapeutic target in human colorectal cancer
- (2013) Antonija Kreso et al. NATURE MEDICINE
- The role of tumour–stromal interactions in modifying drug response: challenges and opportunities
- (2013) Douglas W. McMillin et al. NATURE REVIEWS DRUG DISCOVERY
- β-Phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype
- (2012) Wen-jing Wu et al. BIOCHEMICAL PHARMACOLOGY
- Exosomes and the Emerging Field of Exosome-Based Gene Therapy
- (2012) Aisling O’Loughlin et al. CURRENT GENE THERAPY
- Drug Transporters in Drug Efficacy and Toxicity
- (2011) M.K. DeGorter et al. Annual Review of Pharmacology and Toxicology
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
- (2011) Lydia Alvarez-Erviti et al. NATURE BIOTECHNOLOGY
- Secreted Monocytic miR-150 Enhances Targeted Endothelial Cell Migration
- (2010) Yujing Zhang et al. MOLECULAR CELL
- Bmi1 is essential in Twist1-induced epithelial–mesenchymal transition
- (2010) Muh-Hwa Yang et al. NATURE CELL BIOLOGY
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- Proteomic Analysis of Human Parotid Gland Exosomes by Multidimensional Protein Identification Technology (MudPIT)
- (2009) Mireya Gonzalez-Begne et al. JOURNAL OF PROTEOME RESEARCH
- Quantitative Proteomic Profiling of Prostate Cancer Reveals a Role for miR-128 in Prostate Cancer
- (2009) Amjad P. Khan et al. MOLECULAR & CELLULAR PROTEOMICS
- Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer
- (2008) S. Ambs et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More